AUTHORS
Michael D. Bern, MD, PhD, Nicole A. Dallas, BS2, Nichole Helton, MS3, Daniel R. George, BA4, Sai Mukund Ramakrishnan, MS5, Christopher A. Miller, PhD6, Timothy Ley, MD7
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Acute myeloid leukemia (AML) is an aggressive myeloid malignancy that causes ~11,500 deaths per year in the United States. First-line therapy for young, medically-fit patients is intensive induction chemotherapy with cytarabine (AraC) and an anthracycline (“7+3”) followed by consolidation with high-dose AraC and/or an allogeneic hematopoietic cell transplant. Approximately 25% of patients fail to achieve a complete remission after 7+3, and these “Primary-Refractory” patients have poor overall survival. As such, there is an unmet clinical need to develop better treatment options for patients with chemoresistant AML. Overexpression of the transcription factor MECOM (due to chromosome 3q26-rearrangements or other mechanisms) is seen in 5-10% of AML patients and is associated with chemotherapy resistance. However, it is currently unclear whether targeting MECOM could potentially promote leukemia clearance or sensitize AML cells to chemotherapy. To evaluate MECOM as a potential therapeutic target, we utilized a previously described mouse model (“Mecom-TO”) with doxycycline-inducible Mecom expression (Ayoub et al. Nature Communications. 2018). MecomTO/+ x Rosa26rtTA/+ bone marrow (BM) chimeras were treated with doxycycline (dox) chow to activate Mecom expression, which led to spontaneous development of AML with a median leukemia-free survival of ~9 months. All viably cryopreserved AMLs were transplantable into secondary recipients maintained on dox chow. We performed whole genome sequencing on 13 independent Mecom-TO AMLs, which demonstrated that all leukemias were clonal in origin, and many AMLs spontaneously acquired cooperating mutations in genes that are recurrently altered in human AMLs (e.g. NrasG13D, NrasG12S, BcorLF1640-1641T, Arid2W266*, Kmt2aT1311I, chr11p amplification involving Ncor1). RNA-seq identified enrichment in NFKB and P53 pathway genes in Mecom-TO AMLs compared to pre-leukemic Mecom-TO hematopoietic cells after 1-3 months of dox treatment.
To determine whether Mecom-TO AMLs are “addicted” to MECOM, recipient mice (Ly5.1+) were fed dox chow until AML cell (Ly5.2+) engraftment was documented, followed by withdrawal of dox, leading to a 40-fold downregulation of Mecom RNA expression within 2 days (p<0.0001). Dox withdrawal led to clearance of Mecom-TO AML cells over 3-4 weeks with a peak leukemia burden of 87% Ly5.2+ cells after 1 week, followed by a decrease to 0.05% after 16 weeks, which was associated with increased survival (p=0.0029). Similar results were observed with 3 independent spontaneous Mecom-TO AMLs with different cooperating mutations. Dox withdrawal also resulted in AML clearance in immunodeficient Ly5.1 Rag1-/- recipient mice, suggesting that AML clearance was not mediated by the adaptive immune system. Flow cytometry and RNA-seq were performed on BM cells from leukemic mice 2, 6, and 9 days after dox withdrawal, which showed downregulation of stem/progenitor markers (e.g. Kit, CD34) and upregulation of mature myeloid markers (e.g. CD33, CCR2) after dox withdrawal. Flow cytometry on BM AML cells 15 days after dox withdrawal showed an increased percentage of Annexin V+ cells compared with mice treated with continuous dox chow (6.98% vs 18.02%; p=0.0002). These results suggest that Mecom downregulation in Mecom-TO AML cells leads to differentiation followed by apoptosis and AML clearance. To evaluate whether Mecom downregulation also sensitizes AML cells to chemotherapy, mice engrafted with Mecom-TO AML were treated with continuous dox chow or withdrawn from dox for 2 days prior to treatment with AraC 100mg/kg or saline IP daily for 5 days. AMLs from mice treated with continuous dox were relatively resistant to AraC compared to mice withdrawn from dox (2-fold vs 124-fold reduction in geometric mean AML burden after AraC, p<0.0001), suggesting that continuous Mecom expression directly promotes AraC resistance in AML cells.
These studies demonstrate that AML initiated by Mecom overexpression remains “addicted” to Mecom after transformation and acquisition of cooperating mutations. Additionally, Mecom overexpression directly promotes chemotherapy resistance in AML cells. These results suggest that targeting MECOM itself may be an effective therapeutic approach for AMLs that overexpress MECOM.
DISCLOSURES
Michael D. Bern, MD, PhD: No relevant conflicts of interest to declare.